Kyverna Therapeutics is trading 9.02% lower at $5.75 in pre-market on October 6, 2026; no October 6 company announcement explaining the decline was identified. - It closed at $6.32 on October 5, after a modest gain in the prior session. - Investor relations lists September 24 as its latest press release, reporting positive one-year clinical data. - Broader indices are higher in pre-market, and available evidence does not point to market-wide weakness as the cause.